Roche Pharmaceutical Development and Sales Overview
Tominersen (RG6042, HTT ASO)
Antisense oligonucleotide (ASO) targeting human HTT mRNA
Indication
Phase/study
# of patients
Phase III
Generation HD1
N=791
ARM A: Tominersen 120mg q2w
ARM B: Tominersen 120mg q4m
ARM C: Placebo q2w
Design
Primary endpoint
Status
CT Identifier
ā
CUHDRS globally
TFC USA only
"
FPI Jan 2019
Huntington's disease
Roche
Phase III
GEN-EXTEND
N=1,050
OLE study in patients participating in prior Roche and Genentech sponsored
studies
ARM A: Tominersen 120mg q2w
ARM B: Tominersen 120mg q4m
Long term safety, tolerability
FPI Q2 2019
Q1 2019 protocol modified to allow for bi-monthly vs four-monthly
dosing, FPI for new protocol July 2019
Recruitment completed Q2 2020
Dosing stopped in Q1 2021 based on IDMC recommendation regarding
the potential benefit/risk profile for study participants. No new safety
signals identified.
Data presented at EHDN and CHDI 2022
Dosing stopped in Q1 2021
NCT03761849
NCT03842969
In collaboration with lonis Pharmaceuticals
CUHDRS=composite Unified Huntington's Disease Rating Scale; TFC=total function capacity; HTT=Huntingtin; OLE=Open Label Extension; IDMC-Independent Data Monitoring Committee; CHDI-Huntington's Disease Association of
Ireland; EHDN-European Huntington's Disease Network
125
NeuroscienceView entire presentation